Integra LifeSciences Holdings C (IART) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.59
- Estimate
- $0.56
- Surprise
- +5.5%
- Revenue (period 2026-09-30)
- $411.2M
- Score today
- 4.8/10
Revenue source: xbrl.
How the report landed
Integra LifeSciences Holdings C (IART) beat the $0.56 estimate with adjusted EPS of $0.59 — a clear 5.5% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates IART Sell at 4.8/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +5.5% surprise compares with a +14.8% four-quarter average. Next scheduled report: 2027-02-25.
What argues against it
- Concentration risk — Product: CSS segment (70.0%)
- Target reached (-6.1% upside)
- Risk below floor (2.5 < 2.5)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $14.52
- Stop
- $13.50
The stock trades at 84.5× trailing but 6.1× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 70 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-11-10 — shown for context, not personalized investment advice.
IART at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $1.12B
- P/E (fwd)
- 6.1
- P/E (ttm)
- 84.5
- 52-week range
- $8.70–$20.49
- Off 52-week high
- 29.1%
- RSI (14)
- 70
- Volume vs avg
- 0.26×
- Score today
- 4.8/10